150 related articles for article (PubMed ID: 23436266)
1. Clinical risk factors for adverse events in allopurinol users.
Ryu HJ; Song R; Kim HW; Kim JH; Lee EY; Lee YJ; Song YW; Lee EB
J Clin Pharmacol; 2013 Feb; 53(2):211-6. PubMed ID: 23436266
[TBL] [Abstract][Full Text] [Related]
2. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
[TBL] [Abstract][Full Text] [Related]
3. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.
Stamp LK; Taylor WJ; Jones PB; Dockerty JL; Drake J; Frampton C; Dalbeth N
Arthritis Rheum; 2012 Aug; 64(8):2529-36. PubMed ID: 22488501
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of allopurinol in chronic kidney disease.
Thurston MM; Phillips BB; Bourg CA
Ann Pharmacother; 2013 Nov; 47(11):1507-16. PubMed ID: 24259601
[TBL] [Abstract][Full Text] [Related]
5. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
Panomvana D; Sripradit S; Angthararak S
J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
[TBL] [Abstract][Full Text] [Related]
6. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
7. Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan.
Yang CY; Chen CH; Deng ST; Huang CS; Lin YJ; Chen YJ; Wu CY; Hung SI; Chung WH
JAMA Intern Med; 2015 Sep; 175(9):1550-7. PubMed ID: 26193384
[TBL] [Abstract][Full Text] [Related]
8. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.
Jung JW; Song WJ; Kim YS; Joo KW; Lee KW; Kim SH; Park HW; Chang YS; Cho SH; Min KU; Kang HR
Nephrol Dial Transplant; 2011 Nov; 26(11):3567-72. PubMed ID: 21393610
[TBL] [Abstract][Full Text] [Related]
9. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
10. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
[TBL] [Abstract][Full Text] [Related]
11. Safety of urate-lowering therapies: managing the risks to gain the benefits.
Keenan RT
Rheum Dis Clin North Am; 2012 Nov; 38(4):663-80. PubMed ID: 23137576
[TBL] [Abstract][Full Text] [Related]
12. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.
Dalbeth N; Stamp L
Semin Dial; 2007; 20(5):391-5. PubMed ID: 17897242
[TBL] [Abstract][Full Text] [Related]
13. Opportunities for improving medication use and monitoring in gout.
Singh JA; Hodges JS; Asch SM
Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
[TBL] [Abstract][Full Text] [Related]
14. Urate-lowering therapy for gout: focus on febuxostat.
Love BL; Barrons R; Veverka A; Snider KM
Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048
[TBL] [Abstract][Full Text] [Related]
15. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
Stevenson M; Pandor A
Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
[TBL] [Abstract][Full Text] [Related]
16. Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
Prescrire Int; 2009 Apr; 18(100):63-5. PubMed ID: 19585722
[TBL] [Abstract][Full Text] [Related]
17. Association between adverse reactions to allopurinol and exposures to high maintenance doses: implications for management of patients using allopurinol.
Paisansinsup T; Breitenstein MK; Schousboe JT
J Clin Rheumatol; 2013 Jun; 19(4):180-6. PubMed ID: 23669799
[TBL] [Abstract][Full Text] [Related]
18. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
Dalbeth N; Kumar S; Stamp L; Gow P
J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for acute kidney injury by non-steroidal anti-inflammatory drugs in patients with hyperuricaemia.
Moon KW; Kim J; Kim JH; Song R; Lee EY; Song YW; Lee EB
Rheumatology (Oxford); 2011 Dec; 50(12):2278-82. PubMed ID: 22019809
[TBL] [Abstract][Full Text] [Related]
20. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
